Trial to Assess the Shedding,Immunogenicity, and Safety of FluMist Administered to Healthy Individuals 5-49 Years of Age
NCT ID: NCT00192140
Last Updated: 2007-12-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
345 participants
INTERVENTIONAL
2004-06-30
2005-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* To describe the duration of shedding of vaccine viruses in individuals 5-49 years of age.
* To describe the genotypic and phenotypic stability of shed vaccine viruses.
* To describe the immune responses of FluMist in individuals 5-49 years of age.
* To describe the safety of FluMist in individuals 5-49 years of age in relation to shedding and the immune response
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
FluMist
FluMist
A single intranasal dose of FluMist will be administered to approx. 300 subjects.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FluMist
A single intranasal dose of FluMist will be administered to approx. 300 subjects.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* In good health;
* Individual or parent/guardian available by telephone;
* Ability of the participant or parent/guardian to understand and comply with the requirements of the protocol; and
* Signed informed consent and HIPAA authorization by the participant or parent/guardian.
Exclusion Criteria
* History of hypersensitivity to gentamicin;
* Close contact who is immunocompromised within the same household;
* Known or suspected immune deficiency diseases or immunosuppressed or have altered or compromised immune status as a consequence of treatment with immunosuppressive therapies;
* History of chronic underlying medical conditions such as chronic disorders of the cardiovascular and pulmonary systems, chronic metabolic diseases (including diabetes), renal dysfunction, or hemoglobinopathies;
* History of Guillain-Barré syndrome;
* History of asthma or reactive airways disease;
* Acute febrile (\>100.0°F oral) and/or respiratory illness, within the 72 hours prior to enrollment;
* For children and adolescents - use of aspirin or aspirin containing products in the month prior to enrollment or anticipated use during the study;
* Pregnancy or, in biologically capable women (e.g., menses within the last year), not willing to agree to acceptable birth control for three months after enrolling into the study (for those biologically capable, a urine pregnancy test must be performed on the day of vaccination with a negative result);
* Administration of any intranasal medication within two weeks prior to enrollment or expected receipt during this study;
* Administration of any live virus vaccine within one month prior to enrollment or if receipt of another live virus vaccine is expected within one month of the vaccination in this study;
* Administration of any inactivated vaccine within two weeks prior to enrollment or if receipt of another inactivated vaccine is expected within two weeks of the vaccination in this study;
* Participation in another investigational trial or administration of any investigational drug within one month prior to enrollment or during this study;
* Employees of the research center, any individuals involved with the conduct of the study, or any family member of such individuals;
* Laboratory confirmed influenza (positive culture or rapid antigen test) in the prior influenza season (2003/2004 or 2004/2005 season);
* Receipt of any influenza vaccine in the prior influenza season; and
* Any condition that in the opinion of the investigator would interfere with the interpretation or evaluation of the vaccine.
5 Years
49 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
MedImmune LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
MedImmune Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert Walker, MD
Role: STUDY_DIRECTOR
Sponsor GmbH
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
SFBC International, Inc
Miami, Florida, United States
Children's Memorial Hospital
Chicago, Illinois, United States
Kentucky Pediatric / Adult Research, Inc
Bardstown, Kentucky, United States
University of Maryland, School of Medicine
Baltimore, Maryland, United States
Center for Vaccine Development
St Louis, Missouri, United States
Creighton University Medical Center
Omaha, Nebraska, United States
Pediatric Clinical Trials International
Columbus, Ohio, United States
Primary Physician's Research Inc.
Pittsburgh, Pennsylvania, United States
Vanderbilt University Medical Center North
Nashville, Tennessee, United States
University of Virginia, Elson Student Health Center
Charlottesville, Virginia, United States
Marshall University Medical Center
Huntington, West Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FM026
Identifier Type: -
Identifier Source: org_study_id